Carl Hull (Co-founder and CEO since 2014) purchased $942,000 of stock on the 25th of November at $26.94. The company recently floated at $27. There was significant subscription by both directors and executives in the IPO with 5 directors spending in total over $3 million and 2 executives spending in total over $700,000. The number and size of these subscriptions and the material investment by the CEO are very encouraging. We are ranking the stock +1.
![$MRVI US Maravai Lifesciences ranked positive on Dec 1st 2020 Smart Insider $MRVI US Maravai Lifesciences ranked positive on Dec 1st 2020](https://www.smartinsider.com/wp-content/uploads/2021/01/MRVI.png)